Evidence map›Paper›PMID 36072552›Full record

ArticleiScience2022

The

Shin'ya Ohmori, Jun Takai, Satoshi Uemura, Akihito Otsuki, Tetsuya Mori, Kinuko Ohneda, Takashi Moriguchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shin'ya OhmoriDepartment of Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.
Jun TakaiDivision of Medical Biochemistry, Tohoku Medical Pharmaceutical University, Sendai, Japan.
Satoshi UemuraDivision of Medical Biochemistry, Tohoku Medical Pharmaceutical University, Sendai, Japan.
Akihito OtsukiDivision of Genomics and Disease Prevention, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Tetsuya MoriDepartment of Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.
Kinuko OhnedaDivision of Genomics and Disease Prevention, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Takashi MoriguchiDivision of Medical Biochemistry, Tohoku Medical Pharmaceutical University, Sendai, Japan.
Tohoku Medical and Pharmaceutical University · JPTakasaki University of Health and Welfare · JPTohoku Medical Megabank Organization · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cells serve as a first-line defense of innate immunity. Interleukin-6 (IL-6) induced by bacterial lipopolysaccharide (LPS) in mast cells plays a crucial role in antibacterial protection. The zinc finger transcription factor GATA2 cooperatively functions with the ETS family transcription factor PU.1 in multiple mast cell activities. However, the regulatory landscape directed by GATA2 and PU.1 under inflammation remains elusive. We herein showed that a large proportion of GATA2-binding peaks were closely located with PU.1-binding peaks in distal

Indexed as

ImmunologyMolecular biologyMolecular mechanism of gene regulation

Identifiers

PMID36072552
PMCPMC9442365
OpenAlexW4291313484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.